Target intelligence / Profile preview

KillerRed (KR)

Target
KR
Molecular classification
Fluorescent protein (Bulina et al., 2006), Photosensitizer (Bulina et al., 2006)
01

Overview

KillerRed is a dimeric red fluorescent protein derived from the hydrozoan jellyfish chromoprotein anm2CP, specifically engineered to function as a genetically encoded photosensitizer (Bulina et al., 2006). Unlike standard fluorescent proteins, it features a unique water-filled channel that allows molecular oxygen to reach the chromophore, facilitating the production of reactive oxygen species (ROS) such as superoxide upon green light irradiation (Carpentier et al., 2009; Pletnev et al., 2009). This light-induced ROS generation enables the precise destruction of specific cells or the inactivation of fusion proteins through chromophore-assisted light inactivation (CALI) (Waldeck et al., 2009; Jarvela & Linstedt, 2014). While primarily used as a research tool to study protein function and oxidative stress, KillerRed has been explored for potential applications in photodynamic therapy (PDT) for cancer (Bulina et al., 2006; Vegh et al., 2011). However, it is not a traditional therapeutic target like a receptor or enzyme; rather, it serves as an effector molecule or an experimental agent (Evrogen, 2024). Its use is characterized by high phototoxicity and specificity, though challenges such as dimerization and limited light penetration in tissues remain (Takemoto et al., 2013). In disease research, it has been employed to create models of retinal degeneration and to study the mechanisms of cell senescence and apoptosis (Tezuka et al., 2016; Shcherbo et al., 2009).

Other names
KillerRed fluorescent proteinGenetically encoded photosensitizerKR
02

Mechanism of action

KillerRed generates reactive oxygen species (ROS), primarily superoxide and hydrogen peroxide, upon irradiation with green light (540-590 nm) through a Type I photoreaction facilitated by a unique water-filled channel reaching the chromophore (Bulina et al., 2006; Carpentier et al., 2009).

03

Biological functions

Reactive oxygen species generation (Bulina et al., 2006)Phototoxicity (Bulina et al., 2006)Chromophore-assisted light inactivation (CALI) (Waldeck et al., 2009)Cell death induction (Bulina et al., 2006)Apoptosis (Shcherbo et al., 2009)
04

Disease associations

Cancer (Bulina et al., 2006)Retinal degeneration (Tezuka et al., 2016)Aging (Shcherbo et al., 2009)
05

Safety considerations

Dimerization-induced aggregation (Takemoto et al., 2013)Photobleaching (Bulina et al., 2006)Basal toxicity in mitochondria (Wojtala et al., 2015)Limited light penetration in deep tissues (Vegh et al., 2011)
06

Biomarkers

Red fluorescence (Excitation: 585 nm, Emission: 610 nm) (Evrogen, 2024)

Beyond the preview

Go deeper on KillerRed (KR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KillerRed (KR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call